Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lasers in Medical Science
Published in: Lasers in Medical Science 3/2019

01-04-2019 | Original Article

AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway

Authors: Haifeng Yang, Zhenzhou Wan, Cheng Huang, Huabin Yin, Dianwen Song

Published in: Lasers in Medical Science | Issue 3/2019

Login to get access

Abstract

Amphiphysin 1 (AMPH-1) is a nerve terminal-enriched protein and it is a 128-kD protein with three identified functional domains. Some studies found that AMPH-1 was a dominant autoantigen associated with breast cancer and melanoma. However, its function in lung cancer is unknown. Here, we showed that AMPH-1 knockdown dramatically increased cell proliferation, attenuated cell apoptosis, and promoted cell cycle progression in human lung cancer cells. In vivo xenograft studies confirmed that the AMPH-1-knockdown cells were more tumorigenic than the controls. Moreover, we demonstrated that silencing AMPH-1 markedly activated Ras-Raf-MEK-ERK signal pathway. In summary, our results identified the anti-oncogenic function of AMPH-1 in lung cancer in vitro and in vivo. It is proposed that AMPH-1 may have potential as a new therapeutic target in human lung cancer treatment.
Literature
1.
Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181CrossRefPubMed
2.
Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068CrossRefPubMed
3.
Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55:1444–1447PubMed
4.
5.
Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353–1362PubMed
6.
Fisher GH, Wellen SL, Klimstra D et al (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249–3262CrossRefPubMedPubMedCentral
7.
Guerra C, Mijimolle N, Dhawahir A et al (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:111–120CrossRefPubMed
8.
Jackson EL, Willis N, Mercer K et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243–3248CrossRefPubMedPubMedCentral
9.
Ji H, Houghton AM, Mariani TJ et al (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25:2105–2112CrossRefPubMed
10.
Johnson L, Mercer K, Greenbaum D et al (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116CrossRefPubMed
11.
12.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:584–594CrossRef
13.
14.
Mitsuuchi Y, Testa JR (2002) Cytogenetics and molecular genetics of lung cancer. Am J Med Genet 115:183–188CrossRefPubMed
15.
16.
17.
Pittock SJ, Lucchinetti CF, Parisi JE et al (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107CrossRefPubMed
18.
David C, McPherson PS, Mundigl O, de Camilli P (1996) A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acad Sci U S A 93:331–335CrossRefPubMedPubMedCentral
19.
20.
Slepnev VI, Ochoa GC, Butler MH, De Camilli P (2000) Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites. J Biol Chem 275:17583–17589CrossRefPubMed
21.
De Jesus-Cortes HJ, Nogueras-Ortiz CJ, Gearing M, Arnold SE, Vega IE (2012) Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. Neuroreport 23:942–946CrossRefPubMedPubMedCentral
22.
Sekiguchi M, Katayama S, Hatano N, Shigeri Y, Sueyoshi N, Kameshita I (2013) Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch Biochem Biophys 535:257–267CrossRefPubMed
23.
Floyd SR, Porro EB, Slepnev VI, Ochoa GC, Tsai LH, De Camilli P (2001) Amphiphysin 1 binds the cyclin-dependent kinase (cdk) 5 regulatory subunit p35 and is phosphorylated by cdk5 and cdc2. J Biol Chem 276:8104–8110CrossRefPubMed
24.
Wu Y, Matsui H, Tomizawa K (2009) Amphiphysin I and regulation of synaptic vesicle endocytosis. Acta Med Okayama 63:305–323PubMed
25.
Takei K, Slepnev VI, Haucke V, De Camilli P (1999) Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1:33–39CrossRefPubMed
26.
Folli F, Solimena M, Cofiell R et al (1993) Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328:546–551CrossRefPubMed
27.
De Camilli P, Thomas A, Cofiell R et al (1993) The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178:2219–2223CrossRefPubMed
28.
Schmierer K, Grosse P, De Camilli P, Solimena M, Floyd S, Zschenderlein R (2002) Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. Neurology 58:148CrossRefPubMed
29.
Crouzet M, Urdaci M, Dulau L, Aigle M (1991) Yeast mutant affected for viability upon nutrient starvation: characterization and cloning of the RVS161 gene. Yeast 7:727–743CrossRefPubMed
30.
Bauer F, Urdaci M, Aigle M, Crouzet M (1993) Alteration of a yeast SH3 protein leads to conditional viability with defects in cytoskeletal and budding patterns. Mol Cell Biol 13:5070–5084CrossRefPubMedPubMedCentral
31.
Dropcho EJ (1996) Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 39:659–667CrossRefPubMed
32.
Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71:59–72CrossRef
33.
Otsuka A, Hirose K, Kilimann MW, Kamata T (2003) Amphiphysin1 inhibits vitronectin-mediated cell adhesion, spreading, and migration in vitro. Biochem Biophys Res Commun 301:769–775CrossRefPubMed
34.
Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA (2011) C-Raf is required for the initiation of lung cancer by K-Ras (G12D). Cancer Discov 1:128–136CrossRefPubMedPubMedCentral
35.
Janku F, Lee JJ, Tsimberidou AM et al (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6:e22769CrossRefPubMedPubMedCentral
Metadata
Title
AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway
Authors
Haifeng Yang
Zhenzhou Wan
Cheng Huang
Huabin Yin
Dianwen Song
Publication date
01-04-2019
Publisher
Springer London
Published in
Lasers in Medical Science / Issue 3/2019
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-018-2616-4

Other articles of this Issue 3/2019

Lasers in Medical Science 3/2019 Go to the issue

Original Article

Er,Cr:YSGG laser associated with acidulated phosphate fluoride gel (1.23% F) for prevention and control of dentin erosion progression

Original Article

Physicochemical, morphological, and biological analyses of Ti-15Mo alloy surface modified by laser beam irradiation

Original Article

Biochemical changes in injured sciatic nerve of rats after low-level laser therapy (660 nm and 808 nm) evaluated by Raman spectroscopy

Original Article

Efficacy and safety of long pulse Nd:YAG laser versus fractional erbium:YAG laser in the treatment of facial skin wrinkles

Original Article

Clinical effectiveness of multi-wavelength photobiomodulation therapy as an adjunct to extracorporeal shock wave therapy in the management of plantar fasciitis: a randomized controlled trial

Original Article

The effects of photobiomodulation therapy on mouse pre-osteoblast cell line MC3T3-E1 proliferation and apoptosis via miR-503/Wnt3a pathway